Review : Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin
Review : Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin
复制标题
评论：使用人血栓调节蛋白的新型检测方法检测到蛋白 C 抗凝途径的异常
DOI：
10.1177/096120339700600706
复制
发表时间：
1997
期刊：
影响因子：
2.6
通讯作者：
Ikuro Maruyama
中科院分区：
文献类型：
--
作者：
M. Mohri;M. Sata;K. Gomi;Y. Maruyama;M. Osame;Ikuro Maruyama
我们开发了一种使用人血栓调节蛋白（TM）的新检测方法，该方法可检测蛋白C抗凝途径（PC途径）的总体异常。该测定表明TM对凝血酶原酶的抑制程度，其表示为25 ng/ml TM对凝血酶原酶抑制的百分比，称为PIP 25（凝血酶原酶抑制百分比）。我们检测了来自有或没有狼疮抗凝剂（LA）的系统性红斑狼疮（SLE）患者、白雷特病（BD）患者和其他血栓性血管炎患者的血浆样本中的PIP 25，并将其与来自日本健康志愿者的血浆样本中的PIP 25进行了比较。PIP 25在单纯SLE组（35.5 ± 12.8%，P = 0.036）、SLE合并LA组（33.0 ± 13.3%，P = 0.030）和BD组（33.3 ± 13.4%，P = 0.010）明显低于健康对照组（43.5 ± 10.7%，P = 0.010）。PIP 25阳性率为44.2± 8.4%，P = 0.823。提示SLE（LA）和BD患者存在蛋白C抗凝通路异常。
We developed a novel assay using human thrombomodulin (TM), which detected overall abnormalities in the protein C anticoagulant pathway (PC pathway). This assay indicates the degree of inhibition of prothrombinase by TM, which is represented as the percentage of prothrombinase inhibition by 25 ng/ml of TM, termed PIP 25 (Prothrombinase Inhibition Percentage). We examined PIP25 in plasma samples from patients with systemic lupus erythematosus (SLE) with or without lupus anticoagulant (LA), patients with Behret's disease (BD), and patients with miscellaneous thrombotic vasculitis and compared these with the PIP25 of plasma samples from healthy volunteers in Japan. The PIP25s were significantly lower in SLE alone (35.5 ± 12.8%, P = 0.036) and SLE with LA (33.0 ± 13.3%, P = 0.030) and BD (33.3 ± 13.4%, P = 0.010) than those in healthy volunteers (43.5 ± 10.7%). There was no significance between healthy PIP25 and those with miscellaneous thrombotic vasculitis (44.2±8.4%, P = 0.823). These results suggest that the abnormalities of the protein C anticoagulant pathway were present in patients with SLE(LA) and BD.